Ropinirole 5mg tablets

Country: United Kingdom

Bahasa: Inggeris

Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)

Bahan aktif:

Ropinirole hydrochloride

Boleh didapati daripada:

Alliance Healthcare (Distribution) Ltd

Kod ATC:

N04BC04

INN (Nama Antarabangsa):

Ropinirole hydrochloride

Dos:

5mg

Borang farmaseutikal:

Oral tablet

Laluan pentadbiran:

Oral

Kelas:

No Controlled Drug Status

Jenis preskripsi:

Valid as a prescribable product

Ringkasan produk:

BNF: 04090100

Risalah maklumat

Page 1 of 2
PACKAGE LEAFLET: INFORMATION FOR THE USER
REQUIP
® 5MG TABLETS
(ropinirole hydrochloride)
Your medicine is available using the name Requip 5mg
Tablets, but will be referred to as Requip throughout this
leaflet. This medicine is also available in strengths 0.25mg,
1mg and 2mg.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU
START TAKING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or
pharmacist.

This medicine has been prescribed for you only. Do not
pass it on to others. It may harm them, even if their
signs of illness are the same as yours.

IF YOU GET ANY SIDE EFFECTS, TALK TO YOUR DOCTOR OR
PHARMACIST. THIS INCLUDES ANY POSSIBLE SIDE EFFECTS
NOT LISTED IN THIS LEAFLET. SEE SECTION 4.
WHAT IS IN THIS LEAFLET
1.
What Requip is and what it is used for
2.
What you need to know before you take Requip
3.
How to take Requip
4.
Possible side effects
5.
How to store Requip
6.
Contents of the pack and other information
1.
WHAT REQUIP IS AND WHAT IT IS USED FOR
REQUIP IS USED TO TREAT PARKINSON’S DISEASE.
The active ingredient in Requip is ropinirole, which belongs to
a group of medicines called DOPAMINE AGONISTS. Dopamine
agonists affect the brain in a similar way to a natural
substance called dopamine.
People with Parkinson’s disease have low levels of dopamine
in some parts of their brains. Ropinirole has effects similar to
those of natural dopamine, so it helps to reduce the
symptoms of Parkinson’s disease.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE
REQUIP
DO NOT TAKE REQUIP:

if you are ALLERGIC to ropinirole or any of the other
ingredients of this medicine (listed in section 6)

if you have SERIOUS KIDNEY DISEASE

if you have LIVER DISEASE
→
TELL YOUR DOCTOR if you think any of these may apply to
you.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Requip:

if you are PREGNANT or think you may be pregnant

if you are BREAST-FE

Ciri produk

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Ropinirole 5mg Film-Coated Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
One film-coated tablet contains 5.7mg ropinirole hydrochloride,
equivalent to
5mg ropinirole.
Excipient(s) with known effect
Lactose monohydrate – 113.2mg
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Film-coated tablet.
Blue, irregular hexagonal shape film-coated tablets, debossed with
‘W’ on one side
and ‘177’ on the other side.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of Parkinson's Disease under the following conditions:
_ _
-
Initial treatment as monotherapy, in order to delay the introduction
of levodopa.
-
In combination with levodopa, over the course of the disease, when the
effect of
levodopa wears off or becomes inconsistent and fluctuations in the
therapeutic
effect occur (“end of dose” or “on-off” type fluctuations).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology Adults
Individual dose titration against efficacy and tolerability is
recommended.
Ropinirole should be taken three times a day, preferably with meals to
improve gastrointestinal tolerance.
_TREATMENT INITIATION: _The initial dose of ropinirole should be 0.25
mg three
times daily for one week. Thereafter, the dose of ropinirole can be
increased in
0.25mg three times daily increments, according to the following
regimen:_ _
Week
3
Unit dose (mg) of
ropinirole
0.
7
5
Total daily dose (mg)_ _of
ropinirole
2.
2
5
_THERAPEUTIC REGIMEN_: After the initial titration, weekly increments
of 0.5 to
1mg three times daily (1.5 to 3mg/day) of ropinirole_ _may be given.
_ _
A therapeutic response may be seen between 3 and 9 mg/day of
ropinirole. If
sufficient symptomatic control is not achieved, or maintained after
the initial
titration as described above, the dose of ropinirole may be increased
up to
24mg/day._ _
Doses of ropinirole_ _above 24 mg/day have not been studied.
If treatment is interrupted for one day or more, re-initiation by dose
titra